[one week Jun] Hengrui said that it's too late to enter the retail market after the "separation of medicine"; the opening increase of micro core biology is amazing, which is a material that can be made; the list of medical consortiums in 118 cities has been published

This week, the list of medical consortiums in 1.118 cities was released, and the rational allocation of medical resources was 2.what? Class 1 new drugs are directly linked to the Internet 3 The opening of micro core biology has increased dramatically, and the future prospects are promising 4 Kickbacks and bribes still exist How can drug-based doctors be alleviated? The list of medical consortia in 118 cities of the State Administration of Medical Sciences has been published, and medical resources are allocated reasonably On August 13, the general office of the National Health Commission and the office of the State Administration of traditional Chinese Medicine issued the notice on printing and distributing the list of pilot cities for the construction of urban medical consortia, identifying 118 pilot cities for the construction of urban medical consortia The construction of medical consortia is to meet the growing medical services of the masses, focusing on the construction of high-quality and efficient medical and health service system, the implementation of the functional positioning of medical and health institutions, the improvement of regional service capacity, and the improvement of the two-way referral mechanism, so as to realize the transformation of the development mode from taking treatment as the center to taking people's health as the center Medical consortia requires organization members to share medical resources (on the premise of ensuring medical quality, promote mutual recognition of inspection results among different levels and categories of medical institutions in the medical consortia.) Overall planning of personnel allocation (post management shall be carried out to promote the flow of talents to the grassroots level.) Strengthen financial management (realize unified financial management, centralized accounting and overall operation in the Medical Association.) Unified information platform (promote the interconnection of information systems of medical and health institutions at all levels, promote Internet diagnosis and treatment services, and play the role of telemedicine.) At the same time, we need to improve the division of labor and cooperation mechanism within the Medical Association; promote the implementation of the acute and slow treatment mode, actively promote the hierarchical diagnosis and treatment, major disease treatment, minor disease treatment, and implement their own functional positioning; implement the requirements of prevention and treatment; strengthen technical cooperation and business collaboration, give full play to the driving role of technology radiation, strengthen the guidance of member units; and do family doctor signing services According to the State Council document, the supervision of vaccines and traditional Chinese medicine needs to be strengthened again On August 12, the general office of the State Council issued the notice on printing and distributing the key task division plan of national deepening the reform of "releasing management service" and optimizing business environment teleconference According to the notice, the key areas should be supervised, and the top priority should be the areas involving people's life safety and high social concern, such as vaccines, drugs, special equipment and hazardous chemicals, which should be strictly supervised by the whole body, variety and chain The key points include: 1 Establish the inspection system for vaccine manufacturers, and implement the full coverage inspection for all vaccine manufacturers in production Implement the system of sending inspectors to vaccine manufacturers 2 Carry out special treatment on the quality of Chinese herbal pieces Strengthen the daily supervision, product sampling and adverse reaction monitoring of the state organized centralized drug procurement and use of the pilot winning varieties, and urge the enterprises to implement the main responsibility 3 In addition, it is necessary to carry out special governance activities to combat fraud and deception, achieve full coverage of supervision and inspection of designated medical institutions and retail pharmacies nationwide, and publicly expose typical cases of fraud and deception This also means that, with the country's accession to CIH, the rise of the national regulatory level, and the introduction of the new policy, in the near future, all chemical enterprises involving environmental protection and safety issues, such as vaccines, Chinese herbal pieces, 4 + 7 winning varieties, are about to usher in a new round of stricter supervision What is the hot news in the industry? On August 14, Zhejiang Medical Security Bureau issued the notice on opinions and suggestions of public consultation on conformity evaluation of generic drugs and online procurement documents of class 1 new drugs (hereinafter referred to as the "draft") to further improve the procurement of generic drugs and online procurement of class 1 new drugs through quality and efficacy consistency evaluation The draft not only puts forward the specific bidding and procurement policies for generic drugs with consistency evaluation, but also explicitly and directly hangs the network for class 1 new drugs, which causes the industry's focus This time, the scope of direct Internet access was defined: Class 1 new drugs approved for listing and in the monitoring period, including class 1.1 new drugs approved for listing before the implementation of the new registration classification of chemical drugs and class 1 drugs approved for listing after the implementation, class 1 biological products for treatment, class 1 traditional Chinese medicine and natural drugs At the same time, in terms of price, it is stipulated that if there are 10 or more provinces (excluding Guangdong, Fujian, Chongqing and military region, the same below) that purchase online (winning the bid) and actually trade online, they shall purchase online at the lowest price not higher than the national minimum price; if there are less than 10, they shall purchase online at the premise not higher than the national minimum price, after negotiation with Zhejiang Province, including at least 10 tertiary hospitals, Purchase online at the lowest price not higher than the negotiation price On August 13, the national health and Health Commission issued the notice on carrying out the performance appraisal and data quality control of three-level public hospitals in accordance with the principle of localization Among them, 32 indicators of income ratio of auxiliary drugs are mentioned By August 20, all three-level public hospitals shall, in accordance with the requirements of the notice on printing and distributing the first batch of national key monitoring and rational drug use catalogue (chemical and biological products) (GWB YH [2019] No 558), calculate the proportion of auxiliary drug revenue in 2016-2018, and fill in the relevant data in the management platform On August 14, 14 provinces filled the value depressions of high-value consumables with large price linkage, a document on Soliciting Opinions on the preparation of high-value medical consumables for centralized procurement issued by Shaanxi medical insurance bureau came out of the industry The document points out that in accordance with the spirit of the notice of the general office of the State Council on printing and distributing the reform plan of high-value medical consumables, in combination with the arrangement of the first coordination meeting of the inter provincial bidding and Procurement Alliance, in order to give full play to the scale and technical advantages of the alliance, promote the cross regional joint procurement, and further reduce the price of high-value medical consumables, it is proposed to launch the inter provincial bidding and Procurement Alliance high-value medical consumables collection Medium volume purchasing As can be seen from the documents, the purpose of this alliance is to give full play to the advantages of scale and discuss price reduction The opening increase of enterprise information micro core biology is amazing, and the future prospect is expected to be August 12, 2019, when micro core biology shares officially listed on the science and Technology Innovation Board of Shanghai Stock Exchange, and with a rise of 511.85%, it has set a new record for the opening increase of Science and technology innovation board The data shows that the average opening price of 27 previously listed Sci-tech Innovation Board shares rose by 147.90% on the first day of listing and 148.77% on the first day of listing, while the performance of micro core biology was much higher than the average In addition, as of the early closing, the price earnings ratio of micro core biology reached 1291 times, and the issue price earnings ratio was 467.51 times, which set a new record of the issue price earnings ratio of new shares in science and technology innovation board The first day of the rise of microcellular organisms is a historic moment With the background of star product xidaban and the gradual clarity of product line gradient, after years of accumulation, micro core organisms have finally prepared enough ammunition to enter the scientific and technological innovation board The company has 6 projects under research in the clinical trial stage, including xidaban (non-small cell lung cancer) project in the phase II / III clinical trial stage, xidaban (diffuse large B-cell lymphoma) project ready for the phase III clinical trial, theoroni (ovarian cancer), theoroni (small cell lung cancer), theoroni (liver cancer), theoroni (non Hodgkin's lymphoma) Tumor) is in phase II clinical trial Due to the clinical indications, the market space of star product xidaban is relatively limited; in 2016, 2017 and 2018, the sales revenue was RMB 55.7588 million, RMB 92.683 million and RMB 136.7235 million respectively, accounting for 65.33%, 83.88% and 92.57% of the operating revenue, which are the main sources of the company's operating revenue and profit during the reporting period At this point, we can not help but sigh that listing has become the only way for the development of domestic innovative pharmaceutical companies, and the fundraising after listing is bound to accelerate the development of innovative companies Hengrui said it's too late to enter the retail market after "medicine division" On August 15, Xu Yifu, vice president of Hengrui Pharmaceutical Group, detailed the strategic details of the new retail currently being arranged by Hengrui, including the differentiation of Hengrui for the new retail, the core model of DTP pharmacy, the business plan constructed by Hengrui, as well as the key varieties of DTP pharmacy and chronic diseases As early as April 11, Liu Tao, general manager of its integrated products business department, officially announced to enter the pharmaceutical retail market at the 2019 Hengrui pharmaceutical retail strategic customer special invitation meeting, the most complete and detailed new retail strategy explanation issued by its official These specific layouts will undoubtedly lay the basic framework for Hengrui's next new retail strategy In the new retail strategy confirmed by Hengrui, chronic disease is the key product What it is trying to build is a "chronic disease + OTC" retail plan In fact, although the overall proportion of out of hospital market and retail market is not high, the recent actions of major pharmaceutical companies can boldly predict that the profits of the hospital market of large pharmaceutical enterprises are not as good as before, and more intelligent people seem to perceive some clues of the pharmaceutical industry: in order to solve the market environment formed by the delicate relationship among hospitals, pharmaceutical enterprises and the government, the medical industry is unstable If drug division can solve this series of problems, it means that at least outpatient drugs will flow out of the hospital, and the retail market and chronic disease market will be greatly improved It would be more difficult to compete in the retail market then! Content source: e pharmaceutical manager, cypress blue, Sina Pharmaceutical News, yaozhi.com and other statements: this point of view only represents the author, not the position of yaozhi.com, welcome to exchange and supplement in the message area; if you need to reprint, please be sure to indicate the author and source of the article.